FMCG Stock Crashes 50% to 2017 Levels; What Went Wrong and What Could Drive the Next Re-Rating? 

Synopsis: PGHH’s stock has fallen nearly 50% from its peak despite record profits, strong margins, and a consistent dividend track record. Slowing revenue growth, rising competition, and changing consumer preferences have weighed on valuations. However, category leadership, emerging growth segments, and healthcare recovery could help drive the next re-rating.

Procter & Gamble Hygiene & Health Care (PGHH), owner of iconic brands such as Tide, Head & Shoulders and Vicks, has long been considered one of India’s most profitable FMCG businesses. Yet the stock has corrected sharply and now trades near levels seen almost a decade ago. The decline comes despite higher profits, expanding margins, and sustained dividend payouts. 

As competition intensifies and revenue growth remains muted, investors are evaluating whether PGHH’s category leadership, innovation pipeline, and premium product segments can reignite growth and restore market confidence. With a market cap of Rs 29,500 crore, the shares of Procter & Gamble Hygiene and Health Care Ltd are trading at Rs 9,100 and are trading at a PE of 35 compared to their industry’s PE of 40. 

Why Has the Stock Halved?

Until recently, Procter & Gamble Hygiene & Health Care Ltd (PGHH) had been one of the premium FMCG franchises available in India. With its pedigree brands like Whisper and Vicks, strong balance sheet (debt-free), return metrics better than anyone else’s, and good dividend history, the stock commanded premium valuations for most of the past decade. 

However, all of that has changed in recent times. The stock, which used to trade in the range of Rs 18,000–19,000, has undergone a severe correction and currently trades in the neighbourhood of Rs 9,000, back to 2017 levels despite earning significantly more profit than then.

What makes things more interesting is that there hasn’t been any pressure on the balance sheet, nor have there been any issues with either profitability or governance. Rather, the market fears slowing top-line growth and increasing competition coupled with doubts about the future of the company.

Strong Profit Growth but Sales Remain Muted 

The gap between profit growth and revenue growth is one of the most distinctive characteristics of the recent performance of PGHH. As for FY26, the company posted revenues amounting to Rs 4,290 crore, remaining unchanged compared to the preceding year. 

Nevertheless, the profit after tax rose by 19% YoY to Rs 856 crore. The company’s management noted that targeted efforts in terms of productivity, cost control, and saving measures allowed the company to increase its investment capacity while at the same time becoming more profitable.

This is illustrated clearly by the numbers presented. While sales rose from Rs 2,334 crore in FY15 to Rs 4,290 crore in FY26, net profit rose from Rs 346 crore to Rs 856 crore. Operating profit increased from Rs 495 crore to Rs 1,171 crore. In addition, operating margins grew from 21% in FY15 to 27% in FY26. 

Although the numbers show impressive progress made by the company towards becoming more successful and more profitable, recently investors’ attention has been increasingly drawn to the slow top-line growth rate experienced by PGHH in the last few years. This can have a negative effect on the valuation of the company because of high expectations of growth in the FMCG industry.

Why Revenue Growth Has Slowed 

Management noted that the growth in the income stream had been quite slow over the years and discussed the same in detail during the session with investors. According to management, consumer behaviour, media consumption behaviour, and the retail channel have changed dramatically over the last ten years. 

The consumers of today know much more, are much choosier, and have access to many more options as compared to before. On the other hand, the buying path has become highly fragmented owing to the rising importance of quick commerce, social commerce, and digital retail channels.

Consumers have also evolved in terms of demands and expectations according to management. With increasing participation of women in the workforce and lifestyle changes, there is an increasing need for product specialisation. 

Likewise, the healthcare categories have normalised following the pandemic, impacting the growth rate of several categories. While category growth continues to be strong, the growth is happening in selected sub-segments and not broad category growth.

The challenge for PGHH is that while these investments may support long-term growth, they can take time to translate into meaningful revenue acceleration. Consequently, investors who once valued the company primarily for consistent growth have become less willing to pay premium multiples until stronger top-line momentum becomes visible. 

Rising Competition Is Reshaping the Market 

One of the most notable structural problems for PGHH is the intensifying level of competition. According to the management of the company, there are more than 50 new competitors in the feminine hygiene segment during the last decade. They include regional, direct-to-consumer, and niche players.

As a result, the market environment is much more competitive now compared to a few years ago. It means that consumers are faced with numerous options concerning products, marketing campaigns, and promotions. 

Despite the fact that management considers competition as a positive factor for the development of categories, it admitted that today the activity level of competition reached an unprecedented level. Product packaging, communication approaches, and brand positioning became more similar.

The intensifying level of competition is one of the reasons for the declining rate of growth among category leaders. Today PGHH dominates the markets of feminine care and healthcare. However, in order to continue leading, it should invest more efforts into innovation, marketing activities, and attracting customers’ attention. The market doubts that future growth would be easier to reach compared to the earlier stages of categories’ development.

Whisper Remains the Crown Jewel 

Whisper, despite these problems, is one of the strongest brands from its portfolio. The management emphasized the fact that the feminine hygiene category keeps growing at about 7-10% per year and Whisper stays the leader in the market.

The company invested considerable efforts in premiumisation and category building in feminine care products. One of the most successful projects was the expansion of Whisper Nights’ portfolio. 

After conducting consumer research, it became obvious that nighttime protection still was underdeveloped, and many people felt discomfort, leakage issues, and sleep disruption. Based on this finding, the company made product improvements and implemented a special communication strategy for the promotion of nighttime use.

Today almost half of pad users in India choose Whisper’s Nights portfolio. The management stressed the fact that Whisper Nights grows faster than category penetration and stays the most distributed night-care brand in the country.

New Segments Are Driving Category Expansion

While the traditional sanitary pads continue to be the company’s core product category, management consistently mentioned Whisper Period Panties to be one of the most promising areas of growth. According to the management, this category is fast-growing, and Whisper has undisputed leadership here.

The growth figures are impressive indeed. In FY26, the sales of Whisper Period Panties exceeded 10 crore units and grew thrice compared to the last fiscal year. The product achieved significant success both in modern retail and on quick-commerce platforms. As was noted by management, out of every four consumers buying period care products via quick-commerce platforms, one selects period panties, and Whisper leads this category.

For investors, this category might be considered one of the most important future growth engines. While competing categories are relatively mature and crowded, the period panties category offers a relatively new and promising category.

Productivity and Dividends Continue to Support Shareholder Returns 

One of the strengths of the investment thesis that holds true is PGHH’s unparalleled capacity to earn cash and pay out money back to its investors. According to the reports, the company managed to earn about Rs 86 crore in terms of savings due to their productivity initiatives alone in FY26. 

The profits earned were used for innovations, marketing, and distribution purposes and at the same time helped margin expansion. The business model of the company has become highly efficient in the past decade. It was noted by the management that return on equity tripled in the past decade while profit margins increased by almost 200 basis points. 

Apart from this, the company has an outstanding dividend history, having paid out dividends for the last 30 years in succession. Financial statements provide evidence of the above-stated strength as well. 

Payout ratios of dividends have always been higher and exceeded 80% on multiple occasions and 100% on a few occasions as well. This indicates that the management prioritises shareholder returns. In spite of slower revenue growth, investors still benefit from earnings growth, dividends, and operational improvements.

Healthcare Recovery Could Provide Another Growth Lever 

Although feminine care garners a lot of investment interest, the healthcare portfolio remains a crucial part of PGHH’s offerings. The management noted that the healthcare categories witnessed softness in the aftermath of the pandemic owing to the normalisation of demand trends. However, there are some signs of recovery emerging in recent quarters.

The firm continues to innovate in its healthcare portfolio. Product innovation at PGHH includes the launch of Vicks Cough Syrup, Vicks ZzzQuil Natura Sleep Gummies, and enhanced Vicks Cough Drops. It was noted by the management that the new and innovative Vicks Cough Drops portfolio, consisting of bigger lozenges and improved formulations, has posted double-digit offtake growth and is improving market share. 

Likewise, the innovation of the Vicks VapoRub portfolio for nighttime has been posting double-digit growth. Healthcare could be another growth avenue for PGHH provided healthcare demand keeps growing and innovations become successful.

What Could Drive the Next Re-Rating? 

The key point here is the possibility of a re-rating, which may emerge in light of this strong price correction. Management is very positive about the prospects of both feminine care and healthcare businesses for the coming years. Company management is sure that growth of the categories will remain mid-to-high single digits, and the integrated approach to growth is still valid.

There are several potential sources of improvement in investors’ sentiments. First, an acceleration in revenue growth will be the strongest factor influencing investor behaviour. Even though the profitability of the business grows, the continuation of the revenue growth proves that the company is able to adapt to consumers’ changes. 

Second, success in fast-growing businesses like Whisper Nights and Period Panties can prove that the company is able to create new consumption occasions and high-end categories. Third, the revival of the healthcare business can create one more driver of growth.

Equally significant, however, is that the underlying business fundamentals still look solid. PGHH continues to dominate its categories, produce healthy cash flow, enjoy excellent margins, and pay out dividends to shareholders. Over the last decade, revenues and profits have more than doubled, return on equity has gone up three times, and shareholder returns have amounted to over Rs 3,000 per share cumulatively.

In this regard, the stock’s performance seems to be less driven by declining fundamentals and more by the worries of the investors concerning potential future growth. If the management manages to prove that the money spent on innovation, premiumisation, customer engagement, and category development translate into revenue growth, the market will start to reassess the company’s outlook. 

Having fallen by nearly 50% off its high and having come back to valuations observed years ago, the next chapter in the story will likely come down to the ability of PGHH to convince the market that growth has come back to the business.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post FMCG Stock Crashes 50% to 2017 Levels; What Went Wrong and What Could Drive the Next Re-Rating?  appeared first on Trade Brains.